Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,283.00-3.50%ETH$2,230.23-4.09%GOLD$3,965.10-1.64%OIL$103.96+1.92%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARCT

Arcturus Therapeutics Holdings Inc.

Healthcare · Biotechnology

$12.15

Up+$0.08 (+0.66%)

Updated Oct 30, 2026, 1:06 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
233.85M
P/E ratio
-3.35
Dividend yield
0.00%
52-week range
$5.50 – $17.96
Volume
474.76K
Avg. volume
553.54K

Price performance · ARCT

ARCT price history

1M range · 0 trading sessions · Daily adjusted prices

ARCT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARCT news

The latest Smart Investors Daily articles mentioning ARCT.

Stock researchCompany · Overview

ARCT research

Overview

Company profile and research snapshot.

Company profile

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$54.00
Implied upside
—
Analysts
—
ARCT recent ratings
DateFirmRatingTarget
Oct 9, 2026Leerink PartnersOutperform—
Sep 24, 2026BTIGBuy—
Sep 24, 2026CitigroupBuy—
Jul 2, 2026Freedom BrokerBuy—
Mar 18, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

SAN DIEGO, October 26, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5th and will also host a conference call and webcast at 4:30 pm Eastern Time on November 5, 2026.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By